New drug formulations of colony-stimulating factors in oncohematology

Cover Page

Cite item

Full Text

Abstract

The use of colony-stimulating factors became an autonomous approach in complex supportive care of blood tumors. By indications of granulocyte colony-stimulating factor (G-CSF) it is possible to reduce of neutropenic period, perform an optimal timing of therapy, decrease a number of infection complications. The development and active use of a new G-CSF drug formulation – pegfilgrastim do not decrease the duration of neutropenic period significantly, but reduced the frequency of drug administration, period of hospitalization and a probability of “ineffective” hematopoietic stem cell mobilization.
In the current issue it is presented the results of modern studies, which demonstrate advantages of PEG-G-CSF in contrast to G-CSF, algorithm for febrile neutropenia risk assessment, the questions for G-CSF administrations in patients with blood tumors.

About the authors

T. T. Valiev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-1469-2365

Timur Teymurazovich Valiev

115478, Moscow, Kashirskoe Shosse, 24
119991, Moscow, Trubetskaya St., 8, Build. 2

Russian Federation

R. R. Fatkhullin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-5988-8428

115478, Moscow, Kashirskoe Shosse, 24

Russian Federation

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0001-8443-8816

143081, Moscow region, Lapino, 1st Uspenskoe Shosse, 111

Russian Federation

P. A. Zeynalova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0003-1564-424X

119991, Moscow, Trubetskaya St., 8, Build. 2
143081, Moscow region, Lapino, 1st Uspenskoe Shosse, 111

Russian Federation

References

  1. Caetano Dos Santos F.L., Michalek I.M., Wojciechowska U. et al. Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999–2020. Ann Hematol 2022;101(5):1059–65. doi: 10.1007/s00277-022-04758-2
  2. Baryakh E.A., Kremenetskaya A.M., Kravchenko S.K. et al. A new short intensive protocol BL-M-04 for therapy of Burkitt lymphoma in adults: intermediate results. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2006;51(6):3–11. (In Russ.).
  3. Valiev T.T., Morozova O.V., Popa A.V., Mentkevich G.L. Treatment outcomes for Burkitt’s lymphoma in children. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2012;57(S3):34. (In Russ.).
  4. Akhmerzaeva Z.Kh., Parovichnikova E.N., Troitskaya V.V. et al. 10-year milestone: long-term survival rates in patients with acute Ph-negative lymphoblastic leukemia according to the ALL-2009 protocol (results of the Russian research group on acute lymphoblastic leukemia study). Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(Suppl. 1):58. (In Russ.).
  5. Aleskerova G.A., Shervashidze M.A., Popa A.V. et al. Treatment results of acute lymphoblastic leukemia in children according to the ALL IC-BFM 2002 protocol. Onkopediatriya = Oncopediatrics 2016;3(4):302–8. (In Russ.). doi: 10.15690/onco.v3i4.1635
  6. Engert A., Bredenfeld H., Döhner H. et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006;91(4):546–9.
  7. Snegovoy A.V., Kagoniya L.M., Kononenko I.B. et al. Practical recommendations for colony-stimulating factors administration to prevent febrile neutropenia development in cancer patients. Zlokachestvennye opukholi = Malignant tumors 2015;(4, special issue):342–9. (In Russ.). doi: 10.18027/2224-5057-2015-4s-342349
  8. Bariakh E.A., Tiurina N.G., Vorob’ev V.I. et al. Therapy for Burkitt’s lymphoma according to the BL-M-04 protocol: 12-year experience. Terapevticheskii arkhiv = Therapeutic Archive 2015;87(7):4–14. (In Russ.). doi: 10.17116/terarkh20158774-14
  9. Valiev T.T., Shervashidze M.A., Osipova I.V. et al. Protocol ALL-IC BFM 2002: outcomes of pediatric acute lymphoblastic leukemia treatment under multi-center clinical trial. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2022;15(2):119–29. (In Russ.). doi: 10.21320/2500-21392022-15-2-119-129
  10. Lee Y.M., Lockwood C. Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis. Int J Nurs Pract 2013;19(6):557–76. doi: 10.1111/ijn.12099
  11. Gurieva O.D., Savelyeva M.I., Valiev T.T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2021;8(4):60–70. (In Russ.). doi: 10.21682/2311-1267-2021-8-4-60-70
  12. Tsukamoto T., Sogo T., Ueyama T. et al. Chimeric G-CSF receptormediated STAT3 activation contributes to efficient induction of cardiomyocytes from mouse induced pluripotent stem cells. Biotechnol J 2020;15(2):e1900052. doi: 10.1002/biot.201900052
  13. Babicheva L.G., Podvyaznikov S.O. Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer. Opukholi golovy i shei = Head and Neck Tumors 2021;11(3): 72–82. (In Russ.). doi: 10.17650/2222­1468­2021­11­3­72­82
  14. Koumakis G., Vassilomanolakis M., Barbounis V. et al. Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 1999;56(1):28–35. doi: 10.1159/000011926
  15. Molineux G., Kinstler O., Briddell B. et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27(12):1724–34. doi: 10.1016/s0301-472x(99)00112-5
  16. Fishburn C.S. The pharmacology of PEGylation: balancing PG with PK to generate novel therapeutics. J Pharm Sci 2008;97(10):4167–83. doi: 10.1002/jps.21278
  17. Pasut G., Veronese F.M. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012;161(2):461–72. doi: 10.1016/j.jconrel.2011.10.037
  18. Green M.D., Koelbl H., Baselga J. et al. A randomized doubleblind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14(1):29–35. doi: 10.1093/annonc/mdg019
  19. Kubo K., Miyazaki Y., Murayama T. et al. A randomized, doubleblind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol 2016;174(4):563–70. doi: 10.1111/bjh.14088
  20. Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S. Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast. Sovremennaya onkologiya = Journal of Modern Oncology 2016;18(2):48–51. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.